Fructose ingestion acutely stimulates circulating FGF21 levels in humans

Molecular Metabolism

Volumn 4, Issue 1, 2015, Pages 51-57

  Dushay, Jody R ^a   Toschi, Elena ^a   Mitten, Emilie K ^a   Fisher, Ffolliott M ^a   Herman, Mark A ^a,b   Maratos Flier, Eleftheria ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

ChREBP; FGF21; Fructose; Metabolic syndrome

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; FRUCTOSE; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRUCTOSE METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE RESPONSE; HORMONE SYNTHESIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALIA; RODENTIA;

EID: 84920722614     PISSN: 22128778     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmet.2014.09.008     Document Type: Article

References (42)

1. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 2007 Jun, 5(6):426-437.
2. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. The Journal of Clinical Investigation 2005 Jun, 115(6):1627-1635.
3. Dushay J., Chui P.C., Gopalakrishnan G.S., Varela-Rey M., Crawley M., Fisher F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010 Aug, 139(2):456-463.
4. Gimeno R.E., Moller D.E. FGF21-based pharmacotherapy-potential utility for metabolic disorders. Trends in Endocrinology and Metabolism 2014 Jun, 25(6):303-311.
5. Inagaki T., Dutchak P., Zhao G., Ding X., Gautron L., Parameswara V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 2007 Jun, 5(6):415-425.
6. Potthoff M.J., Inagaki T., Satapati S., Ding X., He T., Goetz R., et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences of the United States of America 2009 Jun, 106(26):10853-10858.
7. Christodoulides C., Dyson P., Sprecher D., Tsintzas K., Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. Journal of Clinical Endocrinology & Metabolism 2009 Sep, 94(9):3594-3601.
8. Gälman C., Lundåsen T., Kharitonenkov A., Bina H.A., Eriksson M., Hafström I., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism 2008 Aug, 8(2):169-174.
9. Chavez A.O., Molina-Carrion M., Abdul-Ghani M.A., Folli F., Defronzo R.A., Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009 Aug, 32(8):1542-1546.
10. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Journal of Hepatology 2010 Nov, 53(5):934-940.
11. Zhang X., Yeung D.C.Y., Karpisek M., Stejskal D., Zhou Z.-G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008 May, 57(5):1246-1253.
12. Fisher F.M., Chui P.C., Antonellis P.J., Bina H.A., Kharitonenkov A., Flier J.S., et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010 Nov, 59(11):2781-2789.
13. Bobbert T., Schwarz F., Fischer-Rosinsky A., Pfeiffer A.F.H., Möhlig M., Mai K., et al. Fibroblast growth factor 21 predicts the metabolic syndrome and diabetes type 2 mellitus in caucasians. Diabetes Care 2012 Aug 28, 36(1):145-149.
14. Suomalainen A., Elo J.M., Pietiläinen K.H., Hakonen A.H., Sevastianova K., Korpela M., et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. The Lancet Neurology 2011 Sep, 10(9):806-818.
15. Iizuka K., Takeda J., Horikawa Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Letters 2009 Sep, 583(17):2882-2886.
16. Sánchez J., Palou A., Picó C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology 2009 Dec, 150(12):5341-5350.
17. Lin Z., Gong Q., Wu C., Yu J., Lu T., Pan X., et al. Dynamic change of serum FGF21 levels in response to glucose challenge in human. Journal of Clinical Endocrinology & Metabolism 2012 Jul, 97(7):E1224-E1228.
18. McGuinness O.P., Cherrington A.D. Effects of fructose on hepatic glucose metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 2003 Jul, 6(4):441-448.
19. Koo H.-Y., Miyashita M., Cho B.H.S., Nakamura M.T., Simon Cho B.H. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochemical and Biophysical Research Communications Elsevier Inc. 2009 Dec, 390(2):285-289.
20. Expert Panel on Detection Evaluation and T of HBC in a. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). The Journal of the American Medical Association 2001 May 16, 285(19):2486-2497.
21. Hudgins L.C., Parker T.S., Levine D.M., Hellerstein M.K. Adual sugar challenge test for lipogenic sensitivity to dietary fructose. Journal of Clinical Endocrinology & Metabolism 2011 Mar, 96(3):861-868.
22. Parks E.J., Skokan L.E., Timlin M.T., Dingfelder C.S. Dietary sugars stimulate fatty acid synthesis in adults. Journal of Nutrition 2008 Jun, 138(6):1039-1046.
23. Tran C., Jacot-descombes D., Lecoultre V., Fielding B.A., Carrel G., Lê K.-A., et al. Sex differences in lipid and glucose kinetics after ingestion of an acute oral fructose load. British Journal of Nutrition 2010 Jun, 1:1-9.
24. Ludvik B., Nolan J.J., Roberts A., Baloga J., Joyce M., Bell J.M., et al. Anoninvasive method to measure splanchnic glucose uptake after oral glucose administration. The Journal of Clinical Investigation 1995 May, 95(5):2232-2238.
25. Cox C.L., Stanhope K.L., Schwarz J.M., Graham J.L., Hatcher B., Griffen S.C., et al. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein- 4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutrition & Metabolism (London) 2012 Jul 24, 9(1):68.
26. Stanhope K.L., Schwarz J.M., Keim N.L., Griffen S.C., Bremer A.A., Graham J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. The Journal of Clinical Investigation 2009 May, 119(5):1322-1334.
27. Iizuka K., Miller B., Uyeda K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. American Journal of Physiology. Endocrinology and Metabolism 2006 Aug, 291(2):E358-E364.
28. Poupeau A., Postic C. Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors. Biochimica et Biophysica Acta. Elsevier B.V. 2011 Aug, 1812(8):995-1006.
29. Benhamed F., Denechaud P., Lemoine M., Robichon C., Moldes M., Bertrand-Michel J., et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. The Journal of Clinical Investigation 2012 Jun 1, 122(6):2176-2194.
30. Mishkin D., Sablauskas L., Yalovsky M., Mishkin S. Fructose and sorbitol malabsorption in ambulatory patients with functional dyspepsia: comparison with lactose maldigestion/malabsorption. Digestive Diseases and Sciences 1997 Dec, 42(12):2591-2598.
31. Gibson P.R., Newnham E., Barrett J.S., Shepherd S.J., Muir J.G. Review article: fructose malabsorption and the bigger picture. Alimentary Pharmacology & Therapeutics 2007 Feb 15, 25(4):349-363.
32. David E.S., Cingari D.S., Ferraris R.P. Dietary induction of intestinal fructose absorption in weaning rats. Pediatric Research 1995 Jun, 37(6):777-782.
33. Choi Y.K., Johlin F.C., Summers R.W., Jackson M., Rao S.S.C. Fructose intolerance: an under-recognized problem. American Journal of Gastroenterology 2003 Jun, 98(6):1348-1353.
34. De Sousa-Coelho A.L., Relat J., Hondares E., Pérez-Martí A., Ribas F., Villarroya F., et al. FGF21 mediates the lipid metabolism response to amino acid starvation. Journal of Lipid Research 2013 Jul, 54(7):1786-1797.
35. Laeger T., Henagan T.M., Albarado D.C., Redman L.M., Bray G.A., Noland R.C., et al. FGF21 is an endocrine signal of protein restriction. The Journal of Clinical Investigation 2014 Aug 18, 124(9):3913-3922.
36. Fisher F.M., Chui P.C., Nasser I.a, Popov Y., Cunniff J.C., Lundasen T., et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. Elsevier, Inc 2014 Jul 29, (September):1-11.
37. Lees E.K., Król E., Grant L., Shearer K., Wyse C., Moncur E., et al. Methionine restriction restores a younger metabolic phenotype in adult mice with alterations in fibroblast growth factor 21. Aging Cell 2014 Jun 17, (May):1-11.
38. Chu A.Y., Workalemahu T., Paynter N.P., Rose L.M., Giulianini F., Tanaka T., et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Human Molecular Genetics 2013 May 1, 22(9):1895-1902.
39. Tanaka T., Ngwa J.S., van Rooij F.J.A., Zillikens M.C., Wojczynski M.K., Frazier-Wood A.C., et al. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. American Journal of Clinical Nutrition 2013 Jul 1, 97(6):1395-1402.
40. Herman M.A., Peroni O.D., Villoria J., Schön M.R., Abumrad N.A., Blüher M., et al. Anovel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 2012 May 19, 484(7394):333-338.
41. Eissing L., Scherer T., Tödter K., Knippschild U., Greve J.W., Buurman W.A., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-β and metabolic health. Nature Communications 2013 Feb 26, 4:1528.
42. Kursawe R., Caprio S., Giannini C., Narayan D., Lin A., D'Adamo E., et al. Decreased transcription of ChREBP-α/β isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes: associations with insulin resistance and hyperglycemia. Diabetes 2013 Mar 3, 62(3):837-844.